Main > PSYCHIATRY > Depression > Treatment > Methylphenidate (CNS Stimulant). > Enantiomer. > (S,S)-Enantiomer. > (L-Threo-Methylphenidate). > Patent > Literature > Claim 1: Depression Treat. Method > WithOut Dysphoria: Adm.: > L-Threo-Methylphenidate. Purity > > 95%. Claim 2: Non-Oral Adm.: > IntraVenous. Oral Adm.: SubLingual > Claim 5: Depression Treat. Method > (a) Non-Oral Adm. of L-Threo > Methylphenidate & (b) Oral Adm. of > Conventional Anti-Depressant (II) > Claim 6: (II): Serotonin Reuptake > Inhibitor; Atypical Antidepressant > or TriCyclic Antidepressant. > Claim 7: Serotonin Reuptake Inhib. > Select: Fluoxetine, Fluvoxamine, > Paroxetine, Sertraline, Venlafaxine > Claim 8: Atypical Antidepressant is > Nefazodone or Buproprion. > Claim 9: TriCyclic Antidepressant

---

Claim 9: TriCyclic Antidepressant's subsections
Select: Amitriptyline, Imipramine,

Claim 9: TriCyclic Antidepressant's products
This section has no products